Is it possible we are missing a treatment effect of Lixisenatide because of the heterogeneity present in most Parkinsons groups recruited for clinical trials (in other words Parkinsons is not one disease and we may have recruited a few different subtypes and this watered down the potential effects)
Typically, Glucagon raises blood sugar
"GLP-3" is an informal count of retatrutides three receptors, not a drug class
Currently, the FDA relies on manufacturers to report supply levels, which raises concerns about transparency and whether financial incentives might influence these reports
Mention any history of gastrointestinal issues, pancreatitis, or thyroid disorders, as GLP-1 medications require special monitoring in these conditions
Thats called your Resting Metabolic Rate (RMR)